Vertex Pharmaceuticals Reports Positive Phase 3 Results in Children for Blockbuster CF Drug

Vertex Pharmaceuticals' (NASDAQ:VRTX) blockbuster cystic fibrosis drug Trikafta might soon have a larger addressable market. The company announced Thursday that a phase 3 trial of the drug, in which it was administered to 6- to 11-year-old patients, met both its primary endpoint (for safety and tolerability) and several secondary endpoints.